4SC AG

Please note: The information displayed on this page might be outdated.
4SC AG: An epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. Additional products are 4SC-202, an epigenetic anti-cancer compound that has completed Phase I clinical trial for the treatment of hematological tumors; and 4SC-205, an anti-cancer compound, which has completed Phase I clinical trial for the treatment of solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Hematology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Address:
Fraunhoferstrasse 22
Planegg-Martinsried, 82152
Germany

Company Participants at European Biotech Investor Days 2021

Dr. Jason Loveridge
4SC AG, CEO
Jason Loveridge joined 4SC AG as CEO in September 2016. He has more than 20 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has substantial transactional experience in the sale and partnering of biotechnology assets. Jason Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia, and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia.

Upcoming Company Event Participation

Ownership data is sourced through FactSet.